CICC: Maintaining Ali Health's (00241) “Outperform the Industry” rating target price of HK$4.2

The Zhitong Finance App learned that CICC released a research report stating that it maintained the “outperforming industry” rating of Ali Health (00241), raised the 2025 FY profit forecast by 76.3% to 1.38 billion yuan, and introduced the 2026 FY profit forecast of 1.62 billion yuan for the first time, considering that the company's cost side narrowed and exceeded expectations. Considering the volatile overall valuation of the sector, the target price is HK$4.2. The company announced 2024FY results: revenue of 27.027 billion yuan (+1.0% YoY), net profit of 883 million yuan (+64.9% YoY), adjusted net profit of 1,438 million yuan (+9)

Zhitong FinanceMay 30 21:13 ET

[Broker Focus] SPDB International maintains Ali Health (00241) “holding” rating indicates that FY25 net profit is expected to maintain a high growth rate

Jinwu Financial News | SPDB International Development Research Report shows that Alibaba Health (00241) FY24 revenue/adjusted net profit was +1%/+91%, respectively. Affected by the high sales base of pandemic-related products in the same period last year, the revenue growth rate was relatively flat. However, during the fiscal year, the company effectively controlled the fulfillment fee rate, which led to a strong increase in adjusted net profit that exceeded expectations. The company guided FY25 revenue growth rate of at least 15%, and the net interest rate increased to about 5 pcts (corresponding net profit growth rate of about +76%). According to the bank, the company's revenue growth improved in April-May, and the bank expects to see more clearly the revenue growth recovery data in the interim report. Based on 1

金吾財訊May 29 03:24 ET

Alibaba Health Information Technology's Net Profit May Surge -- Market Talk

0645 GMT - Alibaba Health Information Technology is likely to see its net profit surge in the next two years, according to Citi analysts led by John Yung in a research note. Management guided net prof

WSJMay 29 02:45 ET

Alibaba Health Information Technology Target Price Raised to HK$9.50 From HK$8.00 by Citi>0241.HK

Alibaba Health Information Technology Target Price Raised to HK$9.50 From HK$8.00 by Citi>0241.HK

Dow JonesMay 29 02:39 ET

Despite slow growth, Ali Health is gradually becoming “healthy”

Jinwu Financial News | On May 27, Alibaba Health (00241.HK) announced its annual results for the 2024 fiscal year ending March 31, 2024. During the reporting period, it achieved revenue of 27.027 billion yuan, a slight increase of 1.0% year on year, and realized net profit of 883 million yuan, an increase of 64.6% year on year, with a significant increase in profit against the backdrop of flat revenue growth. The number of members of over 77 million and a MAU of up to 300 million have made Ali Health's current earnings report very popular. Driven by the results, Alibaba Health Hong Kong stock surged 10% on the 28th.

金吾財訊May 29 02:23 ET

Changes in Hong Kong stocks | Alibaba Health (00241) rose more than 4%, annual results beat expectations, institutions expect profit growth to accelerate in FY2025

The Zhitong Finance App learned that Ali Health (00241) rose by more than 4%. As of press release, it rose 4.14% to HK$3.52, with a turnover of HK$200 million. According to the news, Ali Health announced its annual results for the year ended March 31, 2024, with total revenue of 27.026.6 billion yuan; gross profit of about 5.895 billion yuan, an increase of 3.4% over the previous year. Net profit reached 883 million yuan, a year-on-year increase of 64.6%. The adjusted net profit was approximately $1,438 million, an increase of 90.8% over the previous year. Bank of America Securities pointed out that the company's performance for the full year ended at the end of March was better than expected, and revenue trends in major business segments

Zhitong FinanceMay 28 23:17 ET